Recommended Topic Related To:

Betagan

"Dec. 11, 2012 -- The diabetes and obesity epidemics may be fueling a dramatic rise in the number of people with vision problems, a new study suggests.

Rates of vision problems that can't be treated with glasses or contact lenses, know"...

Betagan

Indications
Dosage
How Supplied

INDICATIONS

BETAGAN® (levobunolol) ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended starting dose is one to two drops of BETAGAN® (levobunolol) ophthalmic solution 0.5% in the affected eye(s) once a day. Typical dosing with BETAGAN® (levobunolol) 0.25% is one to two drops twice daily. In patients with more severe or uncontrolled glaucoma, BETAGAN® (levobunolol) 0.5% can be administered b.i.d. As with any new medication, careful monitoring of patients is advised. Dosages above one drop of BETAGAN® (levobunolol) 0.5% b.i.d. are not generally more effective. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with dipivefrin and/or epinephrine, and/or pilocarpine and other miotics, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.

HOW SUPPLIED

BETAGAN® (levobunolol hydrochloride ophthalmic solution USP) Liquifilm® sterile ophthalmic solution is supplied in white opaque plastic dropper bottles as follows:

BETAGAN 0.25%: C Cap® Compliance Cap B.I.D. (twice daily)
  5 mL--NDC 11980-469-25 10 mL--NDC 11980-469-20
BETAGAN 0.5%: Standard Cap C Cap® Compliance Cap C CAP® Compliance Cap
2 mL--NDC 11980-252-02 Q.D.(once daily) B.I.D. (twice daily)
  5 mL--NDC 11980-252-65 5 mL--NDC 11980-252-25
  10 mL--NDC 11980-252-60 10 mL--NDC 11980-252-20
  15 mL--NDC 11980-252-61 15 mL--NDC 11980-252-21

NOTE: Protect from light. Store at 15°-30°C (59°-86°F).

Allergan Inc, Irvine, Califomia 29612, U.S.A. FDA rev date: 4/12/2002

Last reviewed on RxList: 10/20/2008
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.


NIH talks about Ebola on WebMD